P
Petya Apostolova
Researcher at University of Freiburg
Publications - 37
Citations - 1606
Petya Apostolova is an academic researcher from University of Freiburg. The author has contributed to research in topics: Transplantation & Graft-versus-host disease. The author has an hindex of 13, co-authored 29 publications receiving 1017 citations. Previous affiliations of Petya Apostolova include Max Planck Society & University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Robert Zeiser,Andreas Burchert,Claudia Lengerke,Mareike Verbeek,Kristina Maas-Bauer,S K Metzelder,Silvia Spoerl,Markus Ditschkowski,Matyas Ecsedi,Katja Sockel,Francis Ayuk,Salem Ajib,F.S. de Fontbrune,Il-Kang Na,Livius Penter,Udo Holtick,Dominik Wolf,Esther Schuler,Everett Meyer,Petya Apostolova,Hartmut Bertz,Reinhard Marks,Michael Lübbert,Ralph Wäsch,Christoph Scheid,Friedrich Stölzel,Rainer Ordemann,Gesine Bug,Guido Kobbe,Robert S. Negrin,Mats Brune,Alexandros Spyridonidis,Annette Schmitt-Gräff,W.J.F.M. van der Velden,Gerwin Huls,Stephan Mielke,G. U. Grigoleit,Jürgen Kuball,Ryan Flynn,Gabriele Ihorst,Jing Du,Bruce R. Blazar,Renate Arnold,Kröger N,Jakob Passweg,Jörg Halter,Gérard Socié,Dietrich W. Beelen,Christian Peschel,Andreas Neubauer,Jürgen Finke,Justus Duyster,N von Bubnoff +52 more
TL;DR: Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Journal ArticleDOI
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Nimitha R. Mathew,Nimitha R. Mathew,Francis Baumgartner,Lukas Braun,David O’Sullivan,Simone Thomas,Miguel Waterhouse,Tony Andreas Müller,Kathrin Hanke,Kathrin Hanke,Sanaz Taromi,Petya Apostolova,Anna Lena Illert,Wolfgang Melchinger,Sandra Duquesne,Annette Schmitt-Graeff,Lena Osswald,Kai-Li Yan,Arnim Weber,Sonia Tugues,Sabine Spath,Dietmar Pfeifer,Marie Follo,Rainer Claus,Michael Lübbert,Christoph Rummelt,Hartmut Bertz,Ralph Wäsch,Johanna Haag,Andrea Schmidts,Michael Schultheiss,Dominik Bettinger,Robert Thimme,Evelyn Ullrich,Yakup Tanriver,Giang Lam Vuong,Renate Arnold,Philipp Hemmati,Dominik Wolf,Markus Ditschkowski,Cordula A. Jilg,Konrad Wilhelm,C. Leiber,Sabine Gerull,Jörg Halter,Claudia Lengerke,Thomas Pabst,Thomas Schroeder,Guido Kobbe,Wolf Rösler,Soroush Doostkam,Stephan Meckel,Kathleen Stabla,Kathleen Stabla,S K Metzelder,S K Metzelder,Sebastian Halbach,Tilman Brummer,Zehan Hu,Zehan Hu,Joern Dengjel,Joern Dengjel,Björn Hackanson,Christoph Schmid,Udo Holtick,Christof Scheid,Alexandros Spyridonidis,Friedrich Stölzel,Rainer Ordemann,Lutz P. Müller,Flore Sicre-de-Fontbrune,Gabriele Ihorst,Jürgen Kuball,Jan E. Ehlert,Daniel Feger,Eva-Maria Wagner,Jean-Yves Cahn,Jacqueline Schnell,Florian Kuchenbauer,Donald Bunjes,Ronjon Chakraverty,Simon Richardson,Saar Gill,Nicolaus Kröger,Francis Ayuk,Luca Vago,Fabio Ciceri,Antonia M.S. Müller,Takeshi Kondo,Takanori Teshima,Susan Klaeger,Susan Klaeger,Bernhard Kuster,Dennis Dong Hwan Kim,Daniel J. Weisdorf,Walter J.F.M. van der Velden,Daniela Dörfel,Wolfgang Bethge,Inken Hilgendorf,Andreas Hochhaus,Geoffroy Andrieux,Melanie Börries,Hauke Busch,John M. Magenau,Pavan Reddy,Myriam Labopin,Joseph H. Antin,Andrea S. Henden,Andrea S. Henden,Geoffrey R. Hill,Geoffrey R. Hill,Glen A Kennedy,Merav Bar,Anita Sarma,Donal P. McLornan,Ghulam J. Mufti,Betul Oran,Katayoun Rezvani,Omid Shah,Robert S. Negrin,Arnon Nagler,Marco Prinz,Marco Prinz,Andreas Burchert,Andreas Neubauer,Andreas Neubauer,Dietrich W. Beelen,Andreas Mackensen,Nikolas von Bubnoff,Wolfgang Herr,Burkhard Becher,Gérard Socié,Michael A. Caligiuri,Eliana Ruggiero,Chiara Bonini,Georg Häcker,Justus Duyster,Jürgen Finke,Erika L. Pearce,Bruce R. Blazar,Robert Zeiser,Robert Zeiser +141 more
TL;DR: Findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7–IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans.
Journal ArticleDOI
Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Alessandro Prestipino,Alica J. Emhardt,Konrad Aumann,David O’Sullivan,Sivahari P. Gorantla,Sandra Duquesne,Wolfgang Melchinger,Lukas Braun,Slavica Vuckovic,Slavica Vuckovic,Melanie Boerries,Melanie Boerries,Hauke Busch,Hauke Busch,Sebastian Halbach,Sandra Pennisi,Teresa Poggio,Petya Apostolova,Pia Veratti,Pia Veratti,Michael Hettich,Gabriele Niedermann,Mark Bartholomä,Khalid Shoumariyeh,Jonas S. Jutzi,Julius Wehrle,Christine Dierks,Heiko Becker,Annette Schmitt-Graeff,Marie Follo,Dietmar Pfeifer,Jan Rohr,Sebastian Fuchs,Stephan Ehl,Frederike A. Hartl,Susana Minguet,Cornelius Miething,Cornelius Miething,Florian H. Heidel,Nicolaus Kröger,Ioanna Triviai,Tilman Brummer,Jürgen Finke,Anna Lena Illert,Eliana Ruggiero,Chiara Bonini,Justus Duyster,Justus Duyster,Heike L. Pahl,Steven W. Lane,Steven W. Lane,Steven W. Lane,Geoffrey R. Hill,Geoffrey R. Hill,Geoffrey R. Hill,Bruce R. Blazar,Nikolas von Bubnoff,Nikolas von Bubnoff,Erika L. Pearce,Robert Zeiser +59 more
TL;DR: In MPN, constitutive JAK2/STAT3/STAT5 activation, mainly in monocytes, megakaryocytes, and platelets, caused PD-L1–mediated immune escape by reducing T cell activation, metabolic activity, and cell cycle progression, which paving the way for immunomodulatory approaches relying on PD-1 inhibition.
Journal ArticleDOI
GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells
Brent H. Koehn,Petya Apostolova,Jessica M. Haverkamp,Jeffrey S. Miller,Valarie McCullar,Jakub Tolar,David H. Munn,William J. Murphy,Willie June Brickey,Jonathan S. Serody,Dmitry I. Gabrilovich,Vincenzo Bronte,Peter J. Murray,Jenny P.-Y. Ting,Robert Zeiser,Bruce R. Blazar +15 more
TL;DR: In this paper, myeloid-derived suppressor cells (MDSCs) are transferred to lethally irradiated recipients of allogeneic donor hematopoietic grafts, which directly undermines their suppressive capacity.
Journal ArticleDOI
Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy.
Ramon I. Klein Geltink,Ramon I. Klein Geltink,Joy Edwards-Hicks,Petya Apostolova,David O’Sullivan,David E. Sanin,Annette E. Patterson,Daniel J. Puleston,Nina A M Ligthart,Joerg M. Buescher,Katarzyna M. Grzes,Agnieszka M. Kabat,Michal A. Stanczak,Jonathan D. Curtis,Fabian Hässler,Franziska M. Uhl,Mario Fabri,Mario Fabri,Robert Zeiser,Edward J. Pearce,Edward J. Pearce,Erika L. Pearce +21 more
TL;DR: In this paper, transient glucose restriction (TGR) in activated CD8+ effector T (TE) cells metabolically primes effector functions and enhances tumour clearance in mice.